Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from dolutegravir-based regimen to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-1 infection
2017-000308-17Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bictegravir, emtricitabine, tenofovir alafenamide and dolutegravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of subjects with HIV-1 RNA greater than or equal to 50 copies/mL at Week 48. Started Apr 2017; status: completed.
02
Drugs
bictegraviremtricitabinetenofovir alafenamidedolutegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-000308-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000308-17.